✦ LIBER ✦

A phase II randomized controlled trial of a novel male contraception, an intra-vas device

✍ Scribed by L. Song; Y. Gu; W. Lu; X. Liang; Z. Chen

Book ID: 108785261
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 114 KB
Volume: 29
Category: Article
ISSN: 0105-6263
DOI: 10.1111/j.1365-2605.2006.00686.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The contraceptive effect of a novel filt

The contraceptive effect of a novel filtering-type nano-copper complex/polymer composites intra-vas device on male animals

✍ Z.-L. Chen; X.-B. Huang; J.-P. Suo; J. Li; L. Sun 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

✍ R. F. van Vollenhoven; N. Kinnman; E. Vincent; S. Wax; J. Bathon 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 2 views

Induction of a non-encephalitogenic type

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

✍ Steinman, Lawrence; Kappos, Ludwig; Comi, Giancarlo; Panitch, Hillel; Oger, Joel 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 133 KB

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

✍ M. C. Genovese; N. Kinnman; G. de La Bourdonnaye; C. Pena Rossi; P. P. Tak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal